ArticleDiscover oncology2025
Exploring the potential role of ADRB1 as a tumor suppressor gene and prognostic biomarker in pan-cancer analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- miR-19a-3p accelerates the development of melanoma and reduces the prognosis of patients.World journal of surgical oncology · 2026Article
- A systems biology approach to unveil shared therapeutic targets and pathological pathways across major human cancers.Computational and structural biotechnology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe β
methodsWe analyzed ADRB1 expression in different types of cancer and corresponding normal tissues. The correlation between ADRB1 expression and pathological grade, stage and survival of cancers were analyzed. We explored the methylation level of ADRB1 in various cancers. The cBioPortal website was used to determine the mutation characteristics of ADRB1 in cancer tissues. Additionally, the CancerSEA website was employed to explore the correlation between ADRB1 expression and different functional states in cancers. We also analyzed the correlation between ADRB1 expression and immune checkpoint (ICP) genes, tumor mutation burden (TMB), microsatellite instability (MSI), neoantigens and cancer-infiltrating immune cells.
resultsOur results showed that ADRB1 expression was downregulated in the majority of solid cancers. The ADRB1 expression was significantly associated with the prognosis of cancer. High expression of ADRB1 was found to be a protective factor for patients with several types of cancer. In some cancers, ADRB1 expression was associated with clinical pathological stages. Functional relevance analysis indicated the crucial role of ADRB1 in regulating multiple biological behaviors of cancer cells. The expression of ADRB1 was associated with TMB, MSI, neoantigens and immune cell infiltration in cancers.
conclusionsThese comprehensive pan-cancer analysis suggested that ADRB1 plays a protective role in various cancer types, such as skin cutaneous melanoma and lung adenocarcinoma. This may provide a new idea for the clinical treatment of cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.